Streetbeat News

Stock Prices

LEN

JP Morgan has maintained its Neutral rating for Lennar (NYSE:LEN) but lowered its price target from $136.00 to $135.00. Lennar's shares are currently trading up 1.41% over the last 24 hours, at $118.94 per share. A move to $135.00 would account for a 13.5% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 5:00 pm

IONQ

Analysts have provided bullish ratings for IonQ (NYSE:IONQ) within the last quarter, with 6 bullish ratings and 2 indifferent ratings. The average 12-month price target for IonQ has increased by 61.84% from the previous average price target of $10.43 to $16.88.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 5:00 pm

AMD

Analysts have provided a range of ratings for Advanced Micro Devices (NASDAQ:AMD) in the last quarter, with the majority being bullish or somewhat bullish. The average price target for AMD is $153.73, indicating an upside from the current price of $102.8801. This average has increased by 25.35% from the previous average price target of $122.64.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 5:00 pm

PD

Morgan Stanley has maintained its Overweight rating for PagerDuty (NYSE:PD) but lowered its price target from $35.00 to $32.00. PagerDuty's shares are currently trading up 1.44% at $23.89 per share. A move to $32.00 would represent a 33.95% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 5:00 pm

HLX

BTIG has maintained its Buy rating for Helix Energy Solns Gr (NYSE:HLX) and increased its price target from $14.00 to $17.00. This new target price represents a potential increase of 53.57% from the current share price. Helix Energy's shares have risen by 3.36% over the last 24 hours.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 5:00 pm

RGLS

Regulus Therapeutics Inc (NASDAQ:RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The drug was well tolerated with no safety findings and showed increases in disease-related urinary biomarkers. Data from the second cohort, dosed at 2mg/kg, are anticipated in the first quarter of 2024. RGLS shares are down 10.90% at $1.47 on the last check Wednesday.

Portfolio Pulse from Vandana Singh

September 20, 2023 | 4:53 pm

BAC

A significant number of bearish trades have been observed in Bank of America's (NYSE:BAC) options activity. Of the 57 unusual trades detected, 56% were bearish and 43% bullish. The total amount for puts was $185,138 and for calls was $6,473,042. Whales have been targeting a price range from $25.0 to $35.0 for Bank of America over the last 3 months. Analysts from Wells Fargo, HSBC, RBC Capital, and Piper Sandler have given varied ratings and price targets for the bank.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 4:47 pm

AXP

A whale investor has taken a bullish stance on American Express (NYSE:AXP), with 54% of investors opening trades with bullish expectations. The whale has been targeting a price range from $140.0 to $185.0 for American Express over the last 3 months. RBC Capital upgraded its action to Outperform with a price target of $200. The price of AXP is up 0.21% at $159.68.

Portfolio Pulse from Benzinga Insights

September 20, 2023 | 4:47 pm

KVYO

Klaviyo's shares have started trading at $36.75 per share, which is higher than its IPO price of $30 per share.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:46 pm

KVYO

Klaviyo's shares have started trading at $39.47 per share, significantly higher than its IPO price of $30 per share.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 4:45 pm